文献速递头颈神经MR

COVID-19后头颈部毛霉病:MR成像谱与分期

Post COVID-19 Head and Neck Mucormycosis: MR Imaging Spectrum and Staging.
PubMed 文献 · Acad Radiol · 2021-12-15

本研究纳入63例病理证实的COVID-19后头颈部毛霉病患者,由三名放射科医生独立评估MRI影像谱、鼻窦毛霉病特征及窦外延伸,并提出四期分期系统,共识读片作为参考标准。分期系统整体读者间一致性很好(κ=0.817),骨受累和MR分期分别是患者死亡率的显著预测因子(p=0.012和0.033)。

要点

  • COVID-19后头颈部毛霉病MR分期系统读者间一致性很好(κ=0.817)。
  • 影像谱包括局限鼻窦型、上颌面部软组织延伸型、骨延伸型、鼻眶型及颅内延伸型。
  • 骨受累(p=0.012)和MR分期(p=0.033)是患者死亡率的显著预测因子。

核心结论

  • 本研究采用诊断可靠性良好的分期方法定义COVID-19后头颈部毛霉病的影像谱,并识别窦外延伸的风险变量;骨受累和MR分期是患者死亡率的显著预测因子。

研究设计与样本

  • 纳入63例病理证实的COVID-19后头颈部毛霉病患者,均行头颈部MR成像;三名独立放射科医生评估影像谱、鼻窦毛霉病MRI特征及窦外延伸,并采用系统化方法和提出的分类系统进行最终分期,共识读片作为参考影像标准,采用κ统计评估分类系统的诊断可靠性。

关键影像表现/征象

  • 影像谱包括局限鼻窦型(7例,11.1%)、鼻窦伴上颌面部软组织延伸型(28例,44.5%)、鼻窦伴上颌面部骨延伸型(7例,11.1%)、鼻眶型(13例,20.6%)及鼻窦伴颅骨或颅内延伸型(8例,12.7%)。
  • 向眶和脑的窦外延伸与后组筛窦/蝶窦及上颌面部区域受累无显著关联(p>0.05)。

诊断标准与关键数值

  • MR分期为四期:1期7例(11.1%)、2期35例(55.6%)、3期13例(20.6%)、4期8例(12.7%)。
  • 分期系统整体读者间一致性κ=0.817。
  • 骨受累预测患者死亡率p=0.012,MR分期预测患者死亡率p=0.033。

临床应用与阅片要点

  • 可采用所提出的四期MR分期系统对COVID-19后头颈部毛霉病进行分期,该系统读者间一致性很好(κ=0.817)。
  • 阅片时应评估鼻窦病变是否向眶、脑、上颌面部软组织及骨延伸,并注意骨受累与死亡率相关(p=0.012)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To develop a systematic approach for magnetic resonance imaging (MRI) analysis, imaging spectrum, and classification system for the staging of post-COVID-19 head and neck mucormycosis.

METHOD: The study included 63 post-COVID-19 patients with pathologically proven mucormycosis who underwent head and neck MR imaging. Three independent radiologists assessed the imaging spectrum of mucormycosis, MRI characteristics of sino-nasal mucormycosis, and extra-sinus extension, and submitted a final staging using a systematic approach and a proposed categorization system. A consensus reading was considered the reference imaging standard. The kappa statistics were used to assess the categorization system's diagnostic reliability.

RESULTS: The overall interreader agreement of the MR staging system was very good (k-score = 0.817). MR imaging spectrum involved localized sino-nasal mucormycosis (n = 7 patients, 11.1%), sino-nasal mucormycosis with maxillo-facial soft tissue extension (n = 28 patients, 44.5 %), sino-nasal mucormycosis with maxillo-facial bony extension (n = 7 patients, 11.1%), sino-naso-orbital mucormycosis (n = 13 patients, 20.6%), and sino-nasal mucormycosis with cranium or intracranial extension (n = 8 patients, 12.7%). Extra-sinus extension to the orbit and brain did not have significant association with involvement of the posterior ethmoid/sphenoid sinuses and maxillo-facial regions (p > 0.05). MRI-based staging involved four stages: stage 1 (n = 7, 11.1%); stage 2 (n = 35, 55.6%), and stage 3 (n = 13, 20.6%), and stage 4 (n = 8, 12.7%). Involvement of the bone and MR-based staging were significant predictors of patients' mortality p = 0.012 and 0.033, respectively.

CONCLUSION: This study used a diagnostic-reliable staging method to define the imaging spectrum of post-COVID-19 head and neck mucormycosis and identify risk variables for extra-sinus extension.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Metwally, Mobashir, Sweed, et al. Post COVID-19 Head and Neck Mucormycosis: MR Imaging Spectrum and Staging. Acad Radiol. 2021. PMID: 34998684. doi:10.1016/j.acra.2021.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。